AP2877A - Materials and methods for treating viral infections with a cysteamine compound - Google Patents

Materials and methods for treating viral infections with a cysteamine compound

Info

Publication number
AP2877A
AP2877A AP2008004511A AP2008004511A AP2877A AP 2877 A AP2877 A AP 2877A AP 2008004511 A AP2008004511 A AP 2008004511A AP 2008004511 A AP2008004511 A AP 2008004511A AP 2877 A AP2877 A AP 2877A
Authority
AP
ARIPO
Prior art keywords
materials
methods
viral infections
treating viral
cysteamine compound
Prior art date
Application number
AP2008004511A
Other languages
English (en)
Other versions
AP2008004511A0 (en
Inventor
Hao Yi Liang
Francis Chi
Qingfu Xu
Original Assignee
Omega Biopharma Hk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omega Biopharma Hk Ltd filed Critical Omega Biopharma Hk Ltd
Publication of AP2008004511A0 publication Critical patent/AP2008004511A0/xx
Application granted granted Critical
Publication of AP2877A publication Critical patent/AP2877A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AP2008004511A 2005-11-28 2006-11-28 Materials and methods for treating viral infections with a cysteamine compound AP2877A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74058405P 2005-11-28 2005-11-28
US81077306P 2006-06-02 2006-06-02
US81888506P 2006-07-06 2006-07-06
US84702006P 2006-09-25 2006-09-25
PCT/US2006/045652 WO2007062272A1 (en) 2005-11-28 2006-11-28 Materials and methods for treating viral infections with a cysteamine compound

Publications (2)

Publication Number Publication Date
AP2008004511A0 AP2008004511A0 (en) 2008-06-30
AP2877A true AP2877A (en) 2014-03-31

Family

ID=37769370

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2008004511A AP2877A (en) 2005-11-28 2006-11-28 Materials and methods for treating viral infections with a cysteamine compound

Country Status (20)

Country Link
US (2) US8415398B2 (https=)
EP (1) EP1954258B8 (https=)
JP (1) JP5138603B2 (https=)
KR (1) KR101440629B1 (https=)
CN (1) CN102038667A (https=)
AP (1) AP2877A (https=)
AR (1) AR057623A1 (https=)
AU (1) AU2006318355B2 (https=)
BR (1) BRPI0619377A2 (https=)
CA (1) CA2631241C (https=)
DK (1) DK1954258T3 (https=)
ES (1) ES2392976T3 (https=)
IL (1) IL191705A (https=)
MX (1) MX2008006851A (https=)
MY (1) MY141003A (https=)
NZ (1) NZ568464A (https=)
PL (1) PL1954258T3 (https=)
PT (1) PT1954258E (https=)
TW (1) TWI401079B (https=)
WO (1) WO2007062272A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1706104A2 (en) * 2004-01-13 2006-10-04 Omega Bio-Pharma (I.P.2) Limited Methods for treating stress and affecting biological immune systems using a cysteamine compound
AR057623A1 (es) * 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
PT1919458E (pt) 2006-01-27 2012-08-23 Univ California Cisteamina revestida entericamente, cisteamina e seus derivados
WO2009023356A2 (en) * 2007-05-25 2009-02-19 Omega-Biopharma (H.K.) Limited Materials and methods for treating influenza infections
EP2276479B1 (en) 2008-04-15 2014-07-02 SineVir Therapeutics LLC Prodrugs of neuraminidase inhibitors
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
WO2010138419A2 (en) * 2009-05-23 2010-12-02 Obio Pharmaceutical (H.K.) Ltd. Materials and methods for treating viral infections
WO2011094693A1 (en) * 2010-02-01 2011-08-04 Mount Sinai School Of Medicine Interferon-inducing compounds and uses thereof
AU2011241478B2 (en) * 2010-04-15 2016-12-01 Biota Scientific Management Pty Ltd Compound for treatment of respiratory condition or disease
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
TWI649100B (zh) 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
MX377396B (es) 2013-09-12 2025-03-10 Janssen Biopharma Inc Compuestos de azapiridona y usos de los mismos.
US10208045B2 (en) 2015-03-11 2019-02-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
CA3017797A1 (en) 2016-03-17 2017-09-21 Thiogenesis Therapeutics, Inc. Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
GB201609940D0 (en) 2016-06-07 2016-07-20 Novabiotics Ltd Microparticles
US10905660B2 (en) * 2016-06-07 2021-02-02 Novabiotics Limited Microparticles
US11758928B2 (en) 2016-12-15 2023-09-19 Société des Produits Nestlé S.A. Compositions and methods that modulate phosphorus or enzymes in a companion animal
CA3076392A1 (en) 2017-09-20 2019-03-28 Thiogenesis Therapeutics, Inc. Methods for the treatment of cysteamine sensitive disorders
WO2020079186A1 (en) 2018-10-17 2020-04-23 Novabiotics Limited Dosage regime
CN120346194A (zh) * 2020-04-01 2025-07-22 硫创治疗公司 用于治疗乙型冠状病毒感染的半胱胺前体化合物
EP4149451A4 (en) 2020-05-13 2024-06-19 The Regents Of The University Of Michigan Cysteamine for the treatment of sars-cov-2 infection
IL298267A (en) * 2020-05-25 2023-01-01 Novabiotics Ltd Anti-viral therapy
WO2022040045A1 (en) * 2020-08-18 2022-02-24 New Amsterdam Sciences, Inc. Sod mimetic and methods of using same for the treatment of covid-19
AU2022405530A1 (en) * 2021-12-07 2024-07-11 Cila Therapeutic Inc. Anti-viral therapeutic agents and uses thereof
WO2024009307A1 (en) * 2022-07-06 2024-01-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Viroporins blockers/inhibitors as anti-flaviviruses agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554655A (en) * 1991-09-30 1996-09-10 Jess G. Thoene Method of treating HIV infection
DE19817511A1 (de) * 1998-04-20 1999-10-21 Werner Slenczka Antivirale Wirksamkeit der Pantothensäure, des Dexpanthenols und ihrer Derivate. Hemmwirkung auf die Virusreplikation umhüllter Viren durch Blockade des Fusionsvorgangs.

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152180A (en) 1960-08-25 1964-10-06 Studiengesellschaft Kohle Mbh Process for the production of nu-tert-alkyl amides and, if desired, nu-tert. alkyl amines
US3352912A (en) 1963-07-24 1967-11-14 Du Pont Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes
US3538160A (en) 1965-03-24 1970-11-03 Smithkline Corp Pentacyclooctaneamines
US3483254A (en) 1967-01-03 1969-12-09 Merck & Co Inc 2-bornanemethylamines
US3496228A (en) 1967-02-16 1970-02-17 Smithkline Corp Aminotricyclononanes and the salts thereof
US3534084A (en) 1968-10-16 1970-10-13 Squibb & Sons Inc Adamantylamino-naphthyloxypropanols and related compounds
US3592934A (en) 1969-06-20 1971-07-13 Du Pont Pharmaceutical compositions and methods of controlling influenza a virus infection utilizing substituted adamantanes and tricyclo(4.3.1.13.8) undecanes
IT1055560B (it) * 1974-05-02 1982-01-11 Istituto Chemioterapico Derivati pirimidinici e relative composizioni per il trattamento di infezioni virali
US5576351A (en) * 1989-12-29 1996-11-19 Mcgaw, Inc. Use of arginine as an immunostimulator
US5292773A (en) * 1990-02-14 1994-03-08 Hirsch Gerald P Treating aids and HIV infection with methionine
ES2027527A6 (es) * 1990-12-17 1992-06-01 Andromaco Lab Procedimiento para la obtencion de polimeros dotados de actividad antiviral.
DE4103177A1 (de) 1991-02-02 1992-08-06 Boehringer Mannheim Gmbh Thiazolo-(2,3-a)isoindol-derivate und diese enthaltende arzneimittel
US5314917A (en) * 1991-03-22 1994-05-24 E. B. Michaels Research Associates, Inc. Method for inactivating enveloped viruses and sperm
PT100914A (pt) 1991-09-30 1993-10-29 Jess G Thoene Uso de compostos capazes de sofrer uma permuta mista com dissulfureto, com uma ligacao dissulfureto, no tratamento de infeccao por hiv
US5686436A (en) * 1993-05-13 1997-11-11 Hiv Diagnostics, Inc. Multi-faceted method to repress reproduction of latent viruses in humans and animals
WO1995010268A1 (en) * 1993-10-15 1995-04-20 Thoene Jess G Prevention of hiv infection
US5725870A (en) * 1993-10-15 1998-03-10 Thoene; Jess G. Methods, composites and articles for contraception
US5714519A (en) 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
US5684024A (en) 1996-01-25 1997-11-04 Viropharma Incorporated Pyrazole dimers compositions and methods for treating influenza
US5821243A (en) 1996-07-22 1998-10-13 Viropharma Incorporated Compounds compositions and methods for treating influenza
WO1999049860A1 (en) * 1998-03-30 1999-10-07 The Endowment For Research In Human Biology, Inc. Agents and methods for modulation of zinc transfer by metallothionein
US6063383A (en) * 1999-01-28 2000-05-16 Hsu; Wu-Ching Pharmaceutical suppository composites for fever and influenza and method of producing the composites
US6468522B1 (en) 1999-07-22 2002-10-22 University Of Medicine And Dentistry Of New Jersey Controlled release of thioamide moiety-containing therapeutic agents
US6521266B1 (en) 1999-09-23 2003-02-18 Morris A. Mann Composition for growth hormone production and release, appetite suppression, and methods related thereto
RU2175230C1 (ru) 2001-01-23 2001-10-27 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция с противовирусной активностью и способ ее получения
ES2269671T3 (es) * 2001-04-25 2007-04-01 Cobalz Limited Composiciones medicas para su uso en el tratamiento o la prevencion de una insuficiencia de vitamina b12 funcional.
GB2377874B (en) * 2001-07-23 2005-06-22 Walcom Bio Chemicals Ind Ltd Poultry feed and the use thereof
WO2004006900A2 (en) * 2002-07-11 2004-01-22 Immune Network Ltd. Sulphydryl compounds in combination with sulphone or sulphnamide conpounds for use in microbial inflammatory diseases
US8017651B2 (en) * 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
AU2003900064A0 (en) * 2003-01-09 2003-01-23 Penam Investments Pty. Ltd. A method of treatment or prophylaxis of viral infection.
GB2398497A (en) * 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
US20040191295A1 (en) * 2003-03-28 2004-09-30 Locniskar Mary Frances Composition and method for viral inhibition
DE10340845A1 (de) * 2003-09-04 2005-03-31 Flavin-Koenig, Dana F., Dr. Pharmazeutisches Kombinationspräparat, enthaltend Glycyrrhizinsäure, Zink und eine Verbindung, die eine Thiolgruppe oder eine zu dieser metabolisierbare Gruppe enthält
AR057623A1 (es) * 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554655A (en) * 1991-09-30 1996-09-10 Jess G. Thoene Method of treating HIV infection
DE19817511A1 (de) * 1998-04-20 1999-10-21 Werner Slenczka Antivirale Wirksamkeit der Pantothensäure, des Dexpanthenols und ihrer Derivate. Hemmwirkung auf die Virusreplikation umhüllter Viren durch Blockade des Fusionsvorgangs.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDERSON ROBERT, A JR et al *
BERGAMINI,A et al *

Also Published As

Publication number Publication date
MY141003A (en) 2010-02-12
EP1954258B8 (en) 2012-10-10
BRPI0619377A2 (pt) 2011-09-27
US9283198B2 (en) 2016-03-15
EP1954258A1 (en) 2008-08-13
PT1954258E (pt) 2012-10-22
CA2631241A1 (en) 2007-05-31
US8415398B2 (en) 2013-04-09
ES2392976T3 (es) 2012-12-17
KR20080077658A (ko) 2008-08-25
TW200733953A (en) 2007-09-16
AR057623A1 (es) 2007-12-05
HK1123726A1 (en) 2009-06-26
IL191705A (en) 2013-11-28
EP1954258B1 (en) 2012-09-05
NZ568464A (en) 2010-09-30
WO2007062272A1 (en) 2007-05-31
CN102038667A (zh) 2011-05-04
AP2008004511A0 (en) 2008-06-30
TWI401079B (zh) 2013-07-11
PL1954258T3 (pl) 2013-01-31
JP2009517395A (ja) 2009-04-30
DK1954258T3 (da) 2012-10-15
MX2008006851A (es) 2008-10-09
JP5138603B2 (ja) 2013-02-06
AU2006318355B2 (en) 2012-01-12
US20070135525A1 (en) 2007-06-14
CA2631241C (en) 2014-02-11
US20130338113A1 (en) 2013-12-19
AU2006318355A1 (en) 2007-05-31
IL191705A0 (en) 2009-02-11
KR101440629B1 (ko) 2014-09-15

Similar Documents

Publication Publication Date Title
IL191705A0 (en) Materials and methods for treating viral infections with a cysteamine compound
PT2343320T (pt) Anticorpos anti-gitr e as suas utilizações
IL222922A (en) Antibodies against neurophilin-1 and their use
PL1961744T3 (pl) Związek zawierający grupę zasadową oraz jego zastosowanie
PL1899994T3 (pl) Magnetycznie miękkie materiały kompozytowe
PT1973950E (pt) Anticorpos anti-epbh4 e métodos que os utilizam
ZAA200501093S (en) Closures
GB2429966B (en) Shaft-ring gripper
EP1899230A4 (en) HANDLING OF COMPRESSIBLE MATERIALS
GB0608938D0 (en) Particulate material
ZA200805191B (en) Materials and methods for treating viral infections with a cysteamine compound
GB0607000D0 (en) Handling jitter
EP1737676A4 (en) PROCESS FOR PREVENTING EDGE CURING
GB0516245D0 (en) Process, composition and compound
GB0511807D0 (en) Process and compound
IL186059A0 (en) Carbapenem derivatives and processes for the preparation thereof
GB2418909B (en) Material handling
GB2432359B (en) Closure
KR101881516B1 (ko) 신경보호 효과 화합물
GB0511532D0 (en) Particulate materials
GB0523637D0 (en) Process and compounds
GB0616902D0 (en) Closure
GB0422480D0 (en) Material handling
GB2432356B (en) Material handling
ZA200804378B (en) Iminopropene compound and use thereof